Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease

NCT07661056 is registered in ClinicalTrials.gov with Biohaven Therapeutics Ltd. as lead sponsor.

NCT NCT07661056
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07661056 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-blind, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BHV-1300 in the Treatment of Adults With Graves' Disease
Lead sponsor
Biohaven Therapeutics Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
June 26, 2026
Completion date
February 29, 2028
Enrollment
300 (estimated)
Sites
55

Conditions

As the registry lists them; a condition with its own page is linked.

graves disease